Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude
- PMID: 9650543
- DOI: 10.1002/j.1552-4604.1998.tb05791.x
Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude
Abstract
Exposure to high altitude results in significant physiologic changes and may precipitate mountain sickness, ranging from mild symptoms above 2,500 m to severe symptoms above 4,000 m. In a previous study, changes in the pharmacokinetics of meperidine were observed after exposure to high altitude. This study was conducted to investigate whether similar changes occur for acetazolamide, which is prescribed for prophylaxis of acute mountain sickness. Acetazolamide 250 mg was administered orally to young, healthy male volunteers in groups of 12 each: those residing at sea level (group L), these same volunteers on the day after arrival at high altitude (4,360 m, group HA), and volunteers living at high altitude for 10 months or longer (group HC). Serial blood samples were collected for 24 hours and acetazolamide concentrations were measured in whole blood, plasma, and plasma water. The elimination rate constant (lambda z) was significantly increased in group HA compared with group L. Clearance uncorrected for bioavailability (Cl/F) increased significantly in group HA compared with group L, and further increased in group HC. Apparent volume of distribution (Vz/F) was decreased by 17% in group HA compared with group L, and increased by 37% in group HC compared with group HA. Mean residence time (MRT) was significantly decreased in group HA compared with groups L and HC. Erythrocyte (RBC) uptake increased significantly after a significant increase in RBC count in group HC compared with group L. The extent of protein binding (EPB), however, was significantly decreased in group HA compared with groups L and HC. Free acetazolamide concentrations were significantly lower in group HC than in group L 12 hours after administration. Based on these observations, it is suggested that patients travelling to high altitude, especially altitudes above 4,000 m, should be closely monitored and acetazolamide dosage adjusted as necessary.
Similar articles
-
Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude.J Clin Pharmacol. 1996 Jul;36(7):610-6. doi: 10.1002/j.1552-4604.1996.tb04225.x. J Clin Pharmacol. 1996. PMID: 8844443
-
Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers.Int J Clin Pharmacol Ther. 2004 Jun;42(6):314-20. doi: 10.5414/cpp42314. Int J Clin Pharmacol Ther. 2004. PMID: 15222723 Clinical Trial.
-
Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude.Methods Find Exp Clin Pharmacol. 1998 Mar;20(2):133-7. doi: 10.1358/mf.1998.20.2.485649. Methods Find Exp Clin Pharmacol. 1998. PMID: 9604855 Clinical Trial.
-
[Mountaineering and altitude sickness].Ther Umsch. 2001 Jun;58(6):387-93. doi: 10.1024/0040-5930.58.6.387. Ther Umsch. 2001. PMID: 11441701 Review. German.
-
Chronic mountain sickness and the heart.Prog Cardiovasc Dis. 2010 May-Jun;52(6):540-9. doi: 10.1016/j.pcad.2010.02.012. Prog Cardiovasc Dis. 2010. PMID: 20417348 Review.
Cited by
-
Alterations in cerebral blood flow and cerebrovascular reactivity during 14 days at 5050 m.J Physiol. 2011 Feb 1;589(Pt 3):741-53. doi: 10.1113/jphysiol.2010.192534. Epub 2010 Nov 1. J Physiol. 2011. PMID: 21041534 Free PMC article. Clinical Trial.
-
Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study.BMJ Open Sport Exerc Med. 2018 Jan 23;4(1):e000302. doi: 10.1136/bmjsem-2017-000302. eCollection 2018. BMJ Open Sport Exerc Med. 2018. PMID: 29387446 Free PMC article.
-
Influence of cerebral blood flow on central sleep apnea at high altitude.Sleep. 2014 Oct 1;37(10):1679-87. doi: 10.5665/sleep.4080. Sleep. 2014. PMID: 25197804 Free PMC article. Clinical Trial.
-
Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship.J Enzyme Inhib Med Chem. 2024 Dec;39(1):2291336. doi: 10.1080/14756366.2023.2291336. Epub 2023 Dec 11. J Enzyme Inhib Med Chem. 2024. PMID: 38078375 Free PMC article. Review.
-
In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection.Microb Pathog. 2022 Mar;164:105454. doi: 10.1016/j.micpath.2022.105454. Epub 2022 Feb 19. Microb Pathog. 2022. PMID: 35189278 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources